Inflammation Erases a Key Histone Mark, Triggering Iron-Driven Death in Aging Muscle Stem Cells
Chronic inflammaging silences the epigenetic writer KMT5A in muscle stem cells, erasing H4K20me1 and unleashing ferroptosis—a reversible process.
Summary
Researchers discovered that systemic age-related inflammation (inflammaging) drives muscle stem cell (MuSC) loss through an epigenetic mechanism. Inflammatory signals, particularly via CCR2 signaling, suppress the histone methyltransferase KMT5A, causing erosion of the histone mark H4K20me1. Loss of this mark silences genes that protect against ferroptosis—an iron-dependent form of cell death—leading to iron accumulation, reactive oxygen species, and lipid peroxidation in aged MuSCs. Crucially, long-term suppression of systemic inflammation starting at 12 months of age preserved H4K20me1 levels, prevented ferroptosis, maintained MuSC numbers, and improved muscle regeneration and functional recovery in aged mice. This work identifies a druggable epigenetic switch linking chronic inflammation to stem cell aging.
Detailed Summary
Skeletal muscle declines with age partly because muscle stem cells (MuSCs, or satellite cells) become fewer and less functional. While both intrinsic epigenetic changes and extrinsic inflammatory signals are known contributors, how systemic 'inflammaging' mechanistically drives MuSC aging has remained unclear. This study, published in Nature Aging, provides a detailed molecular answer.
Using a multi-omics approach, the authors profiled plasma cytokines and muscle transcriptomics in young versus aged mice. Aged plasma showed markedly elevated pro-inflammatory cytokines (TNF, IL-1α, IL-1β, IL-6, CCL2, CCL7, CCL11, CCL12) alongside increased myeloid cells. Computational integration of blood proteomics with muscle transcriptomics pinpointed CCR2 signaling as a key upstream driver of this inflammatory state. Injecting young mice with CCR2 ligands was sufficient to transiently accelerate MuSC activation and produce long-lasting epigenetic memory, demonstrating that even short-term inflammation has durable cellular consequences.
The central epigenetic finding is that aged MuSCs show a dramatic reduction in H4K20 monomethylation (H4K20me1), a histone mark deposited by the enzyme KMT5A (also known as SET8/PR-Set7). Both Kmt5a mRNA and protein were significantly decreased in freshly isolated aged MuSCs. Mechanistically, inflammatory signals—especially CCL2 via CCR2—suppressed Kmt5a expression, and this suppression could be recapitulated in young MuSCs by exposure to aged serum or direct cytokine treatment. Chromatin immunoprecipitation sequencing (ChIP-seq) revealed that loss of H4K20me1 preferentially occurred at loci encoding anti-ferroptotic genes, including Gpx4, Slc7a11 (xCT), and genes regulating iron homeostasis.
Consequently, aged MuSCs displayed hallmarks of ferroptosis: elevated labile iron pools, increased reactive oxygen species, lipid peroxidation (measured by C11-BODIPY and 4-HNE staining), and cell death reversible by the ferroptosis inhibitor ferrostatin-1 or the iron chelator deferoxamine. Genetic rescue experiments confirmed the causal role of KMT5A: re-expression of Kmt5a in aged MuSCs restored H4K20me1 at anti-ferroptotic gene promoters, rescued gene expression, and blocked ferroptotic death. Conversely, Kmt5a deletion in young MuSCs phenocopied aging.
Critically, long-term anti-inflammatory treatment initiated at 12 months of age (mid-life) preserved Kmt5a expression and H4K20me1 levels in MuSCs, maintained stem cell numbers, reduced ferroptotic markers, and significantly improved muscle regeneration and force recovery after injury in aged mice. These findings establish a linear pathway—systemic inflammation → KMT5A suppression → H4K20me1 erosion → anti-ferroptotic gene silencing → ferroptosis—and suggest that targeting this axis could combat sarcopenia and age-related muscle degeneration.
Key Findings
- Aged mouse plasma has elevated CCR2 ligands (CCL2, CCL7, CCL11, CCL12) that suppress Kmt5a and erode H4K20me1 in MuSCs.
- Loss of H4K20me1 epigenetically silences anti-ferroptotic genes (Gpx4, Slc7a11), triggering iron-dependent cell death in aged MuSCs.
- Ferroptosis inhibitors (ferrostatin-1) and iron chelators rescue aged MuSC survival, confirming ferroptosis as the death mechanism.
- Kmt5a re-expression in aged MuSCs restores H4K20me1, rescues anti-ferroptotic gene expression, and prevents ferroptotic death.
- Anti-inflammatory treatment started at 12 months preserves MuSC numbers and improves muscle regeneration and force recovery in aged mice.
Methodology
The study used multi-omics profiling (plasma proteomics, muscle RNA-seq, ChIP-seq) in young (3–4 month) vs. aged (22–24 month) mice, combined with CCR2 ligand injection models, genetic Kmt5a gain- and loss-of-function experiments in MuSCs, and long-term anti-inflammatory pharmacological intervention starting at 12 months. Ferroptosis was assessed via C11-BODIPY lipid peroxidation, labile iron pool assays, 4-HNE immunostaining, and rescue with ferrostatin-1 or deferoxamine. Muscle function was evaluated by force measurements and histological analysis post-injury.
Study Limitations
The study was conducted entirely in mice, and direct translation to human MuSC aging requires validation in human tissue and clinical cohorts. The specific anti-inflammatory agent used for long-term treatment may have pleiotropic effects beyond CCR2 inhibition, complicating attribution of benefits solely to the described pathway. Additionally, the contribution of other histone marks and epigenetic regulators to ferroptosis susceptibility in MuSCs was not fully explored.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.